" class="no-js "lang="en-US"> Digital Therapeutic Company Pioneer My mHealth Announces Successful Roll-Out of NHS-Approved Diabetes App to the Community of Kent - Medtech Alert
Friday, March 01, 2024

Digital Therapeutic Company Pioneer My mHealth Announces Successful Roll-Out of NHS-Approved Diabetes App to the Community of Kent

My mhealth announces its successful roll-out of their NHS-approved diabetes digital therapeutic platform, myDiabetes, as 100,000 diabetes patients and their clinical services in Kent and Medway can now access the numerous health care benefits and better manage their conditions from the free app.

Since the much-anticipated launch of the roll-out in early April 2021, already over 400 patients have been given access to the myDiabetes platform, with these patients accessing more than 350 educational sessions. In a complete change in the way patients are able to interact with their clinician, patients are given access by their health professional and are then asked to fill in their details such as their blood glucose levels or BMI to support the delivery of the service. This will directly improve patient care by providing greater accessibility to their most important healthcare information.

With diabetes affecting around 1 in 14 people (4.8 million) in the UK1, it’s crucial that the support services bring patients and their clinician closer together while also giving patients greater control over their own healthcare. The myDiabetes app has been designed to empower patients in self-management of their condition with a user-friendly digital programme that offers quick and easy access on smart phones, tablets and computers from anywhere, at any time. The app also provides a unique exercise and diet intervention programme, DMFit to help patients increase their activity and improve their knowledge around nutrition.

In addition, the in-app content is specifically tailored to enable patients to monitor their blood glucose, HbA1C, and other risk factors and access to an expert educational programme allows them to learn about their conditions with the aim of reducing their risk of serious long-term complications. This project will also generate a great deal of invaluable insights into the needs of the patients and how best to support them in the future.

Following the success of the Kent roll-out, my mhealth plans to roll-out the myDiabetes app to a further 30 clinical services before the end of 2021.

Global Transformation Lead for my mhealth, Ian Thompson said:

“Diabetes education is a core component of a patients care. The more an individual knows about their diabetes, the more capable they are to manage their condition and the risks of developing further complications. It’s exciting for us to be working closely with multiple diabetes teams throughout the Kent & Medway area.”

Kent & Medway Diabetes & CVD Transformation and Development Manager, Ian Butcher commented:

“All of us here at the CCG alongside the Paul Carr Diabetes Trust feel this is a really fantastic step forward for people living with Diabetes in Kent. It’s important that we continue to evolve services to ensure we make the best care available. myDiabetes provides an easy-to-use digital self-management tool, with access to an educational programme, targeted evidence-based information and advice. It is designed to complement our existing diabetes services and gives all who use it digital access to tools to better manage their condition for the general improvement of their health and wellbeing.”

Gary Fagg MBE, Chairman of the Paula Carr Diabetes Trust commented:

“The Paula Carr Diabetes Trust are proud to be investing in a partnership with Kent & Medway CCG and my mhealth at this very important time for the NHS. We know first-hand the challenges diabetes patients have in accessing services. Providing the diabetes digital platform, myDiabetes, offers a significant breakthrough to the continuing education and access to services for our diabetes patients across the region.” 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more